Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

Learn about sudden cardiac death risk in people with hypertrophic cardiomyopathy, including risk factors, prevention methods, ...

If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

The Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial was conducted to evaluate the prophylactic implantation of an ICD to prevent sudden death in patients with ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for ...

Capricor plans to commence the filing of a BLA in October of 2024 seeking full approval of deramiocel for the treatment of DMD-cardiomyopathy with full submission expected by year-end 2024. The BLA ...

PHOENIX, Ill. — The parents of a north Phoenix boy with a rare diagnosis are ecstatic to report their son is getting stronger and recovering quickly, thanks to a new treatment at a West Valley ...

LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, ...

Scientists at St. Jude Children’s Research Hospital studied how common and rare genetic variants influence late-onset cardiomyopathy risk, highlighting the unique genetic complexity of childhood ...

Scientists at The Lundquist Institute for Biomedical Innovation have identified a previously unknown molecular safeguard that ...